Trials / Completed
CompletedNCT02082262
AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 140 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 10 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of AGN-229666 for the treatment of seasonal or perennial allergic conjunctivitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGN-229666 | One to two drops of AGN-229666 twice daily in each eye for 10 weeks. |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2014-07-01
- Completion
- 2014-07-01
- First posted
- 2014-03-10
- Last updated
- 2016-03-14
- Results posted
- 2015-10-08
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02082262. Inclusion in this directory is not an endorsement.